US Bioservices Announces Wins in Three Strategic Areas

Feb 07, 2018
By Pharmaceutical Executive Editors

US Bioservices, an independent pharmacy and a part of AmerisourceBergen, announced that 2017 was a record-breaking year for new business wins in three strategic areas—oncology, rare and orphan, and specialty infusion. US Bioservices received access to 28 new products in 2017, including 10 oncology products and three rare and orphan therapies.

US Bioservices’ portfolio offers:

  • Specialty Infusion: US Bioservices has more than 25 years of experience providing specialty infusion therapies, including IV drugs, and self-administered infusion and injection medications, to patients nationwide. US Bioservices offers personalized clinical support, including self-infusion training, in-home infusion nursing services and 24/7 access to clinical support.
  • Oncology: With more than 80 members, US Bioservices’ Oncology Patient Support Team provides clinical care that is specific to the patient’s needs, conditions, and therapies.
  • Rare & Orphan: US Bioservices’ depth of experience supporting rare and orphan programs, combined with AmerisourceBergen’s Signature® commercialization solutions, provide a range of program and partnership options that can be tailored to maximize results.

Through comprehensive technology systems, US Bioservices’ manufacturer partners get a transparent view into the therapy experience.

US Bioservices leverages resources provided by AmerisourceBergen companies, including Lash Group for patient support services; ION Solutions and Oncology Support for their connections to community oncology providers, and ICS and ASD Healthcare for rare and orphan logistics and distribution.

lorem ipsum